NCT03089645 2020-07-27MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.MedImmune LLCPhase 1 Completed39 enrolled
NCT02261220 2020-03-06A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsMedImmune LLCPhase 1 Completed380 enrolled